Loading...
XIDX
PYFA
Market cap371mUSD
Nov 12, Last price  
550.00IDR
Name

Pyridam Farma Tbk PT

Chart & Performance

D1W1MN
XIDX:PYFA chart
P/E
P/S
3.22
EPS
Div Yield, %
Shrs. gr., 5y
27.78%
Rev. gr., 5y
50.70%
Revenues
1.92t
+173.59%
39,639,626,16761,336,546,45986,643,019,272119,580,973,204132,000,542,048140,858,442,443151,094,461,045176,730,979,672192,555,731,180222,302,407,528217,843,921,422216,951,583,953223,002,490,278250,445,853,364247,114,772,587277,398,061,739630,530,235,961715,425,027,099702,067,615,6051,920,811,833,000
Net income
-330.25b
L+287.52%
1,328,422,3341,729,406,2461,743,483,8692,308,877,3293,772,968,3594,199,202,9535,172,045,6805,308,221,3636,195,800,3382,661,022,0013,087,104,4655,146,317,0417,127,402,1688,447,447,9889,342,718,03922,104,364,2675,478,944,087275,241,310,307-85,220,974,920-330,246,642,000
CFO
-141.04b
L+35.64%
000736,542,4085,020,232,1519,538,086,2410-448,715,089-5,856,771,7771,472,541,37115,699,910,4342,827,335,8832,844,360,1871,757,637,35117,609,426,4091,112,220,08039,586,425,851275,241,310,307-103,982,859,768-141,041,645,000
Dividend
May 31, 20194 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, antibiotics, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, and tube stopper. The company also provides skin care products comprising Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel; products in the areas of alimentary t. and metabolism, blood and blood forming organs, cardiovascular system, dermatologicals, G.U. system and sex hormones, systemic corticosteroids, systemic antibacterial, sensory organs, as well as musculo-skeletal, nervous, and respiratory systems; and supplements and other preventive consumer health products with energy drinks and healthy ready-to-drink products. In addition, it engages in the research and development on biotechnology, life, and medical science. The company was founded in 1976 and is headquartered in Jakarta, Indonesia.
IPO date
Oct 16, 2001
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT